What Benactiv Gola Treats: Main Uses and Benefits

The medication is commonly used to provide symptomatic relief from acute symptoms in the throat and oral cavity. Its active ingredient, flurbiprofen, is relevant for the symptomatic management of sore throat, which is its primary therapeutic domain. The product is considered relevant in conditions presenting with acute episodes where symptoms become more noticeable.

It is generally applied in contexts where short-term symptomatic assistance is needed for symptoms related to physical discomfort, such as soreness, pain, and persistent irritation. This medicine plays a role in managing symptom clusters related to inflammatory or irritative states and is relevant for easing symptoms that interfere with daily comfort. It provides support that helps ease the overall symptom burden during difficult episodes.

---

Quick Fact: Relevant for Pain and Symptoms related to Irritation

“The medication is applied across domains where additional symptomatic support is needed, and may assist with maintaining functional stability when symptoms are more noticeable.”

Regulatory References

1. Union Register of medicinal products - European Commission

Benactiv Gola, which contains the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen, is officially authorized for use by adults and adolescents aged 12 years and older. Safety and efficacy are not established, and it is contraindicated for use in children under 12 years.

Contraindications (Must Not Use)

Official regulatory documents define several absolute exclusions for using this medicine:

• Hypersensitivity: Individuals with known allergy to flurbiprofen or any of the product's components, or who have previously experienced asthma, rhinitis, or urticaria after taking aspirin or other NSAIDs.
• Gastrointestinal Disease: Patients with a history of recurrent peptic ulceration/haemorrhage, or active/history of gastrointestinal bleeding or perforation related to previous NSAID therapy.
• Severe Organ Failure: Individuals with severe heart failure, severe renal failure, or severe hepatic failure.
• Pregnancy: Women in the third trimester of pregnancy.

Use with Special Consideration (Not Recommended)

Use is generally not recommended or requires caution for the elderly (due to increased risk of serious adverse reactions), and for women in the first and second trimesters of pregnancy.

This section outlines documented interaction patterns for the active ingredient, Flurbiprofen, as detailed in official government regulatory documents.

Interaction Classifications

Classification	Interacting Entity	Interaction Outcome Stated in Label
Avoided Combination	Other NSAIDs (Nonsteroidal Anti-inflammatory Drugs)	Increased risk of gastrointestinal (GI) ulceration or bleeding (additive pharmacodynamic effect).
Use with Caution	Anticoagulants (e.g., Warfarin)	Enhanced anticoagulant effect, leading to an increased risk of serious bleeding.
Use with Caution	Lithium	Elevation of plasma Lithium levels due to reduced renal clearance.
Efficacy Reduction	Antihypertensives (e.g., ACE inhibitors, Diuretics)	Reduction in the blood pressure-lowering or diuretic effect.

Pharmacokinetic and Timing Constraints

Flurbiprofen is metabolized by the enzyme CYP2C9. Regulatory warnings state that individuals known as CYP2C9 poor metabolizers may exhibit abnormally high plasma concentrations due to reduced metabolic clearance.

Timing separation rules apply to certain combinations. Co-administration with Methotrexate should be viewed with caution, as NSAIDs may increase Methotrexate levels, potentially enhancing toxicity, particularly when administered within a 24-hour window.

Alcohol consumption is formally noted in regulatory summaries as potentially increasing the risk of adverse reactions, including those concerning the gastrointestinal tract.

Targeted Inhibition of the COX Enzyme System

The primary mechanism of Benactiv Gola (Flurbiprofen) involves the inhibition of Cyclooxygenase (COX) enzymes within the arachidonic acid cascade . This action suppresses the synthesis of prostaglandins, which are key lipid mediators modulating local hyperemic and edema-forming processes in the body. By blocking their production, the drug directly alters the signaling output of the arachidonic acid cascade.

---

Localized Modulation of Peripheral Pathways

Flurbiprofen is delivered via lozenge or spray for a highly localized effect on the oropharyngeal tissue. This allows the active ingredient to achieve high concentrations directly at the site of administration . This engagement facilitates the limiting of the propagation of excessive mediator activity within the oropharyngeal mucosa. This mechanism contributes to altered signaling dynamics within the targeted peripheral pathways, leading to downstream modulation of local tissue responses and alteration of local nociceptive and inflammatory signaling pathways.

Instruction Map: How to use Benactiv Gola — Official Administration Guidelines

This section outlines the non-advisory, labeled instructions for the use of Flurbiprofen in its local oromucosal forms.

---

Administration Scope

Feature	Detail
Route of administration	Oromucosal (Local application to the mouth and throat).
Dosing schedule	Lozenge/Spray: One 8.75 mg unit or dose (three spray actuations). Mouthwash: 10 ml of 0.25% solution.
Frequency and timing	Doses may be repeated every 3 to 6 hours, as required. Do not exceed five doses in 24 hours.
Age-group rules	Not indicated for children under 12 years (lozenges) or generally 18 years (spray). No dose reduction is required for patients with mild to moderate renal or hepatic impairment.
Preparation requirements	The oral spray pump must be primed before the first use. Mouthwash may be diluted with water before use.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical/Local
Frequency pattern	As-needed (intermittent use)
Use-context constraints	Strictly limited to short-term use only, not exceeding a maximum of three days.

---

Resulting Procedural Structure

The core administration principle requires using the lowest effective dose for the shortest duration necessary.

Official step sequence:

• Administer the labeled dose to the back of the throat/oral cavity, ensuring the lozenge is sucked slowly and moved around the mouth to prevent irritation.
• Avoid inhalation when applying the oromucosal spray to prevent product dispersal into the respiratory tract.
• Repeat dosing only when the minimum three-hour interval has been observed, maintaining adherence to the five-dose maximum within the 24-hour period.
• Discontinue administration upon reaching the mandatory three-day course duration limit.

---

Connection to the overall use protocol

The official instructions establish a precise, time-bound protocol defined by the oromucosal route and a regulated as-needed frequency that is strictly capped by a maximum dose and duration. This framework explicitly restricts the administration of the medicine to brief, acute episodes for short-term use.

Research Evidence / Overview of Studies for Benactiv Gola (Flurbiprofen)

---

Evidence for Use in Irritative-Inflammatory Conditions of the Oropharyngeal Cavity

Research has primarily explored the use of flurbiprofen in conditions that are characterized by inflammatory or irritative states in the throat, such as sore throat (pharyngitis). The compound was studied within research settings relevant to trials assessing short-term or episodic symptom patterns. These studies were most often short-term randomized controlled trials (RCTs) that monitored patient-reported outcomes describing perceived discomfort. The populations studied generally included non-elderly adults presenting with acute episodes where symptoms become more noticeable.

Studies reported measurements of changes during the study period, particularly related to the patient-reported outcomes describing perceived discomfort and difficulty swallowing. Findings describe patterns observed in the studies where patients reported a change in outcomes related to physical discomfort. However, evidence quality varies across studies, and findings were mixed regarding the magnitude and duration of the changes observed.

---

Evidence for Use Following Dental Procedures

The compound was evaluated in research exploring short-term symptom changes associated with irritative-inflammatory states and pain that may follow conservative or extractive dental procedures. These studies focused on episodes where symptoms become more noticeable following the procedure and research examined how symptoms change over time. Research examined outcomes capturing phases of heightened symptom activity, such as acute pain levels, often measured using patient-reported scales.

Studies explored acute changes and findings indicate patterns related to outcomes describing episodic or acute changes in pain intensity over defined, very short time intervals immediately following the procedure. Data show patterns related to patient-reported outcomes describing perceived discomfort in the immediate post-procedure period.

---

What is Still Uncertain About Benactiv Gola

Evidence highlights what is known—and what is still uncertain—about this compound. Primarily, certainty remains low due to the focus on short-term outcomes and the fact that sample sizes were modest in many of the core studies.

The evidence is limited regarding sustained effects and reported short-term changes outside of temporary use. Long-term effects are not fully established, and comparative evidence is lacking, meaning direct, high-quality head-to-head comparisons against other commonly used options are not broadly available. Furthermore, data for certain groups remain insufficient regarding children under 12 years of age, and research describing effects in the elderly population is limited.

Key Studies & References

1. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial
2. A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
3. Suppression of dental pain by the preoperative administration of flurbiprofen

Common questions about Benactiv Gola (FAQ)

---

Q: Is Benactiv Gola the same as other throat sprays?

According to official product information, Benactiv Gola contains the active ingredient Flurbiprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

This distinguishes it from other throat sprays that may use a different class of medicine, such as a local anesthetic or an antiseptic, to relieve discomfort.

---

Q: Does Benactiv Gola contain an antibiotic?

No, Benactiv Gola does not contain an antibiotic. Its active ingredient, Flurbiprofen, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), which works to relieve pain and inflammation.

---

Q: How quickly should I feel an effect after using Benactiv Gola?

Studies cited in regulatory documents indicate that relief from symptoms may be perceived relatively quickly.

For example, for the lozenge form, the onset of the first perceived pain relief has been shown to occur as early as 11 to 12 minutes after the dose is administered.

---

Q: How long does the feeling of relief from Benactiv Gola typically last?

Official information indicates that the analgesic (pain-relieving) effects of a single dose, as demonstrated in clinical studies, have a duration that typically lasts between 3.5 to 6 hours.

The exact duration of relief may depend on the specific product formulation and individual response.

---

Q: Is Benactiv Gola safe to use if I have high blood pressure?

Regulatory warnings note that medicines in the NSAID class, like Flurbiprofen, may potentially raise blood pressure or reduce the effectiveness of certain blood pressure medications.

Official documents indicate that caution is advised for individuals with high blood pressure.

---

Q: Is it normal to feel a slight tingling sensation after applying Benactiv Gola?

Yes, feelings of localized throat irritation, oropharyngeal discomfort, or a temporary burning/tingling sensation are listed as common side effects in the official safety profile.

These sensations are usually related to the product being applied directly to the throat lining.

---

Q: Does Benactiv Gola work differently than a lozenge for sore throats?

While both the spray and lozenge forms are designed for highly localized action, they are administered differently.

The lozenge form dissolves slowly, which allows for a longer period of contact and a measurable soothing and coating effect on the throat lining, an effect that is not achieved by the spray.

---

Q: Can Benactiv Gola be used if I am breastfeeding?

Regulatory and authoritative sources, such as the NIH LactMed database, indicate that Flurbiprofen is found in breast milk at low levels and is considered unlikely to cause adverse effects in an infant.

However, reviewing use with a healthcare provider is generally suggested.

---

Q: Can Benactiv Gola be used if I have a sensitive stomach?

The official safety documents list absolute exclusions (contraindications) for people with a history of recurrent gastrointestinal issues such as stomach or intestinal ulceration, bleeding, or perforation related to prior NSAID use.

Official documents provide the full contraindication list, which includes specific gastrointestinal conditions.

---

Q: Is Benactiv Gola available without a prescription?

The specific oromucosal forms of Benactiv Gola, such as the lozenges and spray, which are intended for short-term symptomatic relief, are generally classified as non-prescription (Over-The-Counter or OTC) medicines in most regulatory jurisdictions.

---

Q: Does Benactiv Gola have sugar or artificial sweeteners?

The composition varies by product form. Regulatory documents for some lozenge formulations list sugars, specifically glucose and sucrose, as inactive ingredients (excipients).

Conversely, many spray formulations utilize artificial sweeteners, such as saccharin sodium.

---

Q: What should I do if I accidentally swallow too much Benactiv Gola?

Official product information describes potential overdose symptoms as generally mild, including drowsiness, nausea, stomach pain, or a temporary change in consciousness.

In cases of suspected excessive use, regulatory guidance indicates that immediate medical attention may be necessary.

---

Q: Are there any specific foods or drinks that should be avoided when using Benactiv Gola?

Regulatory documents specifically warn against the consumption of alcohol while using this medicine.

The official caution states that alcohol may increase the risk of experiencing adverse reactions, particularly those related to the digestive system.

---

Q: Does Benactiv Gola have a known potential for abuse or dependence?

Official classifications of the active ingredient, Flurbiprofen, categorize it as an NSAID.

It is not designated as a controlled substance under regulatory schedules, meaning it does not have a known potential for abuse or dependence.

---

Q: What happens if I forget a dose of Benactiv Gola?

As Benactiv Gola is designated for 'as-needed' (PRN) use and is strictly limited to short-term duration, regulatory documents do not provide instruction for a 'missed dose.'

Official guidance notes that the minimum recommended interval between doses should be observed when relief is needed.

---

Q: Are there any warnings about using Benactiv Gola before driving or operating machinery?

Official warnings advise caution regarding driving or operating heavy machinery.

This caution is based on reported side effects, which include dizziness and somnolence (drowsiness), that could temporarily impair a person's ability to focus or react.

---

Q: Is Benactiv Gola safe for people with diabetes?

Individual information regarding the composition of the product used should be considered. Official ingredient lists show that some formulations, most notably the lozenges, contain sugars like glucose and sucrose.

Due to the presence of these sugars, information regarding the composition should be considered when assessing carbohydrate intake.

---

Q: Is the color or taste of Benactiv Gola standardized?

The color, taste, and form are standardized according to the specific product formulation and listed flavor.

For example, lozenges are typically described as round with a specific color range and flavor profile, but these characteristics vary across the different flavors available.

---

Q: What are the ingredients that are inactive in Benactiv Gola?

The inactive components (excipients) are listed in regulatory documents and differ based on whether the product is a lozenge or a spray.

These typically include various sweeteners, such as sucrose, glucose, or saccharin sodium, as well as specific flavoring agents and preservatives.

---

Q: Are there any differences in Benactiv Gola formulations across countries?

Official regulatory data confirms that while the active ingredient, Flurbiprofen 8.75 mg, and its core purpose remain consistent internationally, the product is marketed under different brand names in various countries, such as Strepsils Intensive or Benactivdol.

---

Q: Are the side effects of Benactiv Gola long-lasting?

The medicine is authorized only for short-term use, generally not exceeding three days.

The adverse reactions documented in regulatory profiles are typically observed during the period of administration, and therefore, they are generally not considered long-lasting after the medicine is discontinued. Long-term effects of this local form are not fully established.

---

Q: What are the official regulatory approvals for Benactiv Gola?

Benactiv Gola is authorized by national drug regulatory agencies, such as those within the European Union (e.g., HPRA) and the United Kingdom (MHRA).

These approvals are granted under specific marketing authorization numbers that confirm the drug’s composition and intended use.

---

Q: Can Benactiv Gola be used simultaneously with cold and flu medicine?

Official warnings state that simultaneous use with other cold and flu medicines should be avoided.

This is because many such remedies already contain Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or other pain relievers, and simultaneous use could lead to an increased risk of side effects.

---

Q: Is Benactiv Gola available in different flavors?

Yes, the lozenge formulations of Benactiv Gola are available in multiple distinct flavors, such as Lemon and Honey or Sugar-free Orange.

These flavorings are listed as inactive ingredients within the product’s regulatory documentation.

---

Q: What is the risk of an allergic reaction to Benactiv Gola?

Serious allergic reactions, known as hypersensitivity reactions, are possible. These rare but serious events include anaphylaxis and angioedema (swelling of the throat, tongue, or face).

Official documents state that immediate medical attention may be required if symptoms of a serious allergic reaction are experienced.

How to Store and Dispose of Benactiv Gola?

Regulatory documentation defines specific requirements for the storage and disposal of this medicine to maintain its stability and ensure public safety.

Storage Requirement	Official Classification
Temperature Limit	Store below 25 C.
Packaging	Keep in the original package.
Child Access	Keep out of the sight and reach of children.

Disposal Requirements

Proper disposal is required to protect the environment and is defined by official regulatory bodies. Medicines that are no longer needed or have expired must not be thrown away via wastewater or household waste. Instead, users are instructed to consult their pharmacist on how to properly discard these medicines according to local environmental regulations.